Retinal pigment epithelial tear after intravitreal ranibizumab.
OBJECTIVE
To report two cases of a retinal pigment epithelial (RPE) tear after intravitreal injection of 0.05 mg ranibizumab.


METHODS
Observational case report.


METHODS
Two patients with choroidal neovascularization (CNV) resulting from age-related macular degeneration (AMD) were treated with an intravitreal injection of ranibizumab.


RESULTS
Both patients were found to have a RPE tear on follow-up visits at one month, confirmed by optical coherence tomography (OCT) and by fluorescein or indocyanine green angiography.


CONCLUSIONS
RPE tears may occur after intravitreal injection of ranibizumab. Further study is needed to determine whether CNV membranes associated with pigment epithelial detachments (PED) are more likely to develop RPE tears after treatment with anti-vascular endothelial growth factor (anti-VEGF) agents.
Bakri
Sophie J
SJ
Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. bakri.sophie@mayo.edu
Kitzmann
Anna S
AS
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010857:Pigment Epithelium of Eye / Q000187:drug effects* / Q000473:pathology; D000069579:Ranibizumab; D012167:Retinal Perforations / Q000139:chemically induced* / Q000175:diagnosis; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab